Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study
European Spine Journal · 2025
DOI: 10.1007/s00586-025-08747-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Spine Journal, 2025. Verfasst von Hamid Reza Khayat Kashani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran. Hauptthemen laut MEDLINE: Enoxaparin, Intervertebral Disc Degeneration, Postoperative Complications, Rivaroxaban. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: School of Medicine, Shahid Beheshti University of Medical Sciences.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
PURPOSE: Venous thromboembolism (VTE) is a significant postoperative complication. The most recommended prophylactic measures involve using the unfractionated heparin, and low molecular weight heparins. Since oral anticoagulants can be administered orally and are cost-effective, they have recently gained attention as a newer intervention. This study aimed to compare the effects of rivaroxaban, and enoxaparin thromboprophylaxis in degenerative spine surgeries. METHOD: Patients diagnosed with degenerative disc disease, and undergoing spinal surgery were randomly assigned to receive either a subcutaneous injection of 40 mg enoxaparin or 10 mg oral rivaroxaban daily in a non-inferiority trial. The evaluation at two weeks, and three months after surgery included the assessments of VTE and other postoperative complications. RESULT: According to the study protocol, 220 patients were enrolled in the study and included in the intention-to-treat analysis. However, the results were only available for 204 subjects as per-protocol. Ninety-seven in enoxaparin and 107 in rivaroxaban group. VTE was detected in 4 patients (3.6%) in the enoxaparin group, and 2 patients (1.9%) in the rivaroxaban group (P = 0.154). Reoperation rates were significantly higher in the enoxaparin group (P = 0.008). Moreover, the enoxaparin group experienced a significantly longer hospital stay (P = 0.033). However, other outcomes did not show significant differences between two groups (P > 0.05). CONCLUSION: This study shows that rivaroxaban effectively prevents VTE incidence in degenerative disc spinal surgeries which is non-inferior to enoxaparin in terms of VTE prophylaxis. Furthermore, the patients in the rivaroxaban group experienced shorter hospital stays and a lower necessity for reoperation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
- Department of Anaesthesiology, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
- Department of Neurosurgery, Jundishapur University of Medical Sciences, Ahwaz, Iran.
- Department of Surgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Esmaily_hadi@sbmu.ac.ir.
ORCID-Profile: Hamid Reza Khayat Kashani, Sohrab Salimi, Pooyan Alizadeh, Zahra Mohammadi, Naser Kachoueian, Maryam Heli, Hadi Esmaily
Förderung
- School of Medicine, Shahid Beheshti University of Medical Sciences
Zitieren
APA
Kashani, H. R. K., Salimi, S., Alizadeh, P., Paryan, P., Mohammadi, Z., Kachoueian, N., Heli, M., Ghalandari, N., & Esmaily, H. (2025). Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study. European Spine Journal. https://doi.org/10.1007/s00586-025-08747-7
Vancouver
Kashani HRK, Salimi S, Alizadeh P, Paryan P, Mohammadi Z, Kachoueian N, et al. Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study. European Spine Journal. 2025. doi:10.1007/s00586-025-08747-7
BibTeX
@article{Kashani2025,
author = {Kashani, Hamid Reza Khayat and Salimi, Sohrab and Alizadeh, Pooyan and Paryan, Poorya and Mohammadi, Zahra and Kachoueian, Naser and Heli, Maryam and Ghalandari, Nasibeh and Esmaily, Hadi},
title = {Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study},
journal = {European Spine Journal},
year = {2025},
doi = {10.1007/s00586-025-08747-7}
}
EUVIMED